IBDoc® IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. Based on BÜHLMANN’s long-lasting experience with calprotectin assays, IBDoc® provides IBD patients a convenient method for self-testing. CALEX® Valve has been developed for simple and easy-to-handle stool extraction with a valve designed to allow the precise application
Continue Reading
Tag: BÜHLMANN IBDoc®
Benefits for Patients and Healthcare Staff of Routine IBDoc® Use Kathleen Sugrue, Advanced Nurse Practitioner at Mercy University Hospital, Cork (Article courtesy of BÜHLMANN’s UK distributor, Alpha Laboratories.) Highlight from this Perspective Article “Since introducing IBDoc® we get less calls on the helpline because patients can check themselves if they are concerned they are flaring.” “Patients
Continue Reading
Health Canada Licence: 98903, Device class: 3 BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article in the Journal of mHealth (Volume 3, Issue 3), McCombie and colleagues performed a systematic review of IBD symptom monitoring smartphone apps. Highlight from this Article In this study, 233 separate apps were found on
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent interview with Lead Inflammatory Bowel Disease Nurse, Pearl Avery, conducted by BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article “In the six months that we have been working with the IBDoc, one patient was
Continue Reading
In this "Summer Edition" we are pleased to announce the FDA 510 (k) clearance of the BÜHLMANN fCAL® ELISA. We make mention of upcoming meetings where you can find us such as American Association of Clinical Chemistry (AACC) and the Association of Medical Laboratory Immunologists (AMLI) annual meetings. Additionally, we share the exciting happenings pertaining to
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 BÜHLMANN was nominated to receive the Swiss Medtech Award for 2018 for the IBDoc® calprotectin smartphone-based rapid test About Swiss MEDTECH Swiss Medtech was established on 12 June 2017 following the merger of two national medtech organizations, FASMED and Medical Cluster.
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster "The BÜHLMANN IBDoc® adds
Continue Reading
US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article from Amanda Appleton, the Product Manager for Calprotectin at BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article “App technology has the ability not only to improve the health of patients but
Continue Reading
